诊断性JAK2 V617F突变检测的增加：隐匿性真性红细胞增多症是原因吗？ - Suppr | 超能文献

An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?

作者信息

Langabeer Stephen E

机构信息

FRCPath, Cancer Molecular Diagnostics, St. James's Hospital, Dublin 8 D08 E9P6, Ireland.

出版信息

Eur J Intern Med. 2018 Jun;52:e37-e38. doi: 10.1016/j.ejim.2018.03.017. Epub 2018 Apr 3.

DOI:10.1016/j.ejim.2018.03.017

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?诊断性JAK2 V617F突变检测的增加：隐匿性真性红细胞增多症是原因吗？

Eur J Intern Med. 2018 Jun;52:e37-e38. doi: 10.1016/j.ejim.2018.03.017. Epub 2018 Apr 3.

2

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].慢性骨髓增殖性疾病诊断的新方法——JAK2 突变检测

Orv Hetil. 2006 Nov 12;147(45):2175-9.

3

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.慢性骨髓增殖性疾病患者中JAK2 V617F突变的发生率及意义

Ir J Med Sci. 2007 Jul-Sep;176(2):105-9. doi: 10.1007/s11845-007-0026-x. Epub 2007 Apr 18.

4

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].[JAK2V617F突变在慢性骨髓增殖性肿瘤患者中的意义]

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226.

5

[Myeloproliferative diseases caused by JAK2 mutation].由JAK2突变引起的骨髓增殖性疾病

Rinsho Byori. 2009 Apr;57(4):357-64.

6

Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.骨髓增殖性疾病和继发性红细胞增多症中中性粒细胞JAK2突变筛查与PRV-1表达分析的同步进行

Br J Haematol. 2005 Oct;131(2):166-71. doi: 10.1111/j.1365-2141.2005.05743.x.

7

Aquagenic pruritus and the JAK2 V617F mutation.水源性瘙痒与JAK2 V617F突变

Clin Exp Dermatol. 2019 Apr;44(3):e33. doi: 10.1111/ced.13872. Epub 2018 Dec 21.

8

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.骨髓增殖性疾病诊断标准的概念变迁以及骨髓增殖性肿瘤的分子病因学与分类：从1950年的达梅谢克到2005年的万琴克尔及以后

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7.

9

No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.在 2 例真性红细胞增多症伴单克隆 B 细胞异常的患者中，未发现 JAK2(V617F)突变的单克隆 B 细胞。

Acta Haematol. 2012;128(3):183-6. doi: 10.1159/000338831. Epub 2012 Aug 10.

10

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.JAK2（V617F）中一种独特的激活突变是真性红细胞增多症的起源，并为骨髓增殖性疾病带来了新的分类。

Hematology Am Soc Hematol Educ Program. 2005:195-200. doi: 10.1182/asheducation-2005.1.195.

引用本文的文献

1

Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera.开发和验证用于筛查潜在真性红细胞增多症个体的两步序贯算法。

Sci Rep. 2021 Jan 8;11(1):209. doi: 10.1038/s41598-020-80459-y.